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Objective: The aim of this study was to assess the performance of a molecular line probe
assay, GenoType MTBDRplus, for rapid detection of rifampicin and isoniazid resistance
in the Mongolian situation. The sensitivity and specificity of GenoType MTBDRplus to
detect rifampicin and isoniazid resistance-associated mutations in culture specimens
and directly in smear-positive clinical specimens was examined.
Method: 218 MDR-TB subjects aged between 14 and 75 years old from eight districts in
Ulaanbaatar city (between July 2009 and May 2010) were included in this study .The
GenoType Mycobacterium tuberculosis drug resistance first line (MTBDR plus) assay (Hain
Life-science, Nehren, Germany) was tested on 109 clinical isolates and directly on 41
sputum specimens for the ability to detect the resistances. Results were compared with
conventional culture and drug susceptibility testing on solid medium.
Results: The high correlation of the results from GenoType MTBDRplus and conventional
drug susceptibility testing was obtained from this study. The results clearly showed a high
performance of GenoType MTBDRplus with almost 100% accuracy for all the important
indicators, such as sensitivity, specificity, positive and negative predictive values and detec-
tion of rifampicin resistance. Discrepancies were obtained in comparison with DNA
sequencing results.
Conclusions: The Genotype MTBDRplus assay was demonstrated as a rapid, reliable and
highly accurate tool for early detection of MDR-TB through examining smear positive cases.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Mongolia is one of the seven countries with a high burden of
tuberculosis (TB) in the western Pacific Region [1]. Doubling of
case notification rates between the years 1990 and 2007, from
79 to 166 per 100,000 population, presents a serious concern
for the Mongolian health authority. The mortality rate of TB-African Society for Myco
enter for Communicable
95950225; fax: +976 50502
m (B. Buyankhishig).was 2.5 per 100,000 population in 2007 [2]. In 2008, the failure
rate among new smear-positive cases was 6.2%, which was
six times higher than the region’s average. Previous studies
showed a low rate of multi-drug resistant tuberculosis
(MDR-TB) among new cases [1.4% (95% CI 0.7–1.6)], whereas,
the rate was significantly higher [27.5% (95% CI 21.8–34.1)]
in retreatment cases [3]. Importantly, around 24% of emergedbacteriology. All rights reserved.
Diseases, MOH, Campus Nam-Yan-Ju Street, Ulaanbaatar 210648,
700.
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Therefore, rapid and accurate detection of resistant strains
is essential for both efficient treatment and control strate-
gies. Generally, drug susceptibility testing (DST) is performed
by the conventional method, which takes several weeks to
yield a result. Today, advances in molecular technology have
provided rapid systems that shorten the time needed for
MDR-TB detection. Among them, the Genotype MTBDR plus
assay can identify the resistant strains within 1 day. The
MTBDR plus is a polymerase chain reaction (PCR) amplifica-
tion and solid-phase reverse assay which detects mutations
in the rpoB for rifampicin (RIF) resistance, the katG for high-
level isoniazid (INH) resistance, and the inhA for low-level
INH resistance directly from smear-positive sputum [4]. Thus,
this method needs to be studied particularly in the develop-
ing world. The aim of this study was to assess the diagnostic
accuracy of a molecular line probe assay (MTBDR plus assay)
to rapidly detect mutations associated with RIF and INH in
culture specimens and directly in smear-positive clinical
specimens collected from previously treated TB patients in
Mongolia.
Methods and materials
Study setting and population
This study was conducted at the National Reference TB Lab-
oratory located at the National Center for Communicable
Diseases, Ulaanbaatar (UB). This laboratory serves a popula-
tion of approximately 1 million people in the capital city of
Ulaanbaatar. All diagnostic centers in eight districts of UB
participated in the survey. The calculation of the sample size
followed the principles outlined in the WHO/IUATLD guide-
lines [5]. Participant recruitment was based on the results
of sputum smear examination for acid-fast bacillus smear
and culture and sensitivity (AFB). Specimens with culture
negative results, contamination, or growth with other Myco-
bacterium spp. were excluded from further investigation.
Overall, 180 smear-positive specimens from relapse, failure
or default of the treatment outcomes were included in this
study.
Specimen
Two specimens with the highest count of bacilli upon Ziehl–
Neelsen examination were submitted for culture and suscep-
tibility testing on solid media and direct MTBDR plus tests.
Specimens were processed by the conventional N-acetyl-L-
cysteine-NaOH method (1% final NaOH concentration). After
decontamination, the concentrated sediments were sus-
pended in 1.0–1.5 ml sterile phosphate buffer (pH 7.0) and
smears were prepared by the Ziehl–Neelsen staining method.
After inoculation onto solid medium, the leftover sediments
of the decontaminated sputum specimens were stored at
20 C. The leftover sediments of the chosen specimens were
thawed and used for MTBDR plus testing. Sample volumes of
500 microliters (ll) were centrifuged for 15 min at 10,000g, the
supernatant was discarded, and the pellet was re-suspended
in100 ll of distilled water. Subsequently, the suspension wasboiled for 20 min and incubated in a sonic water bath at room
temperature for 15 min [6].
Drug susceptibility testing
Sputum smear microscopy positive samples were cultured on
Lo¨wenstein-Jensen (LJ) culture medium. Mycobacterium tuber-
culosis complex was identified by culturing on LJ medium con-
taining p-nitrobenzoic acid. Drug susceptibility testing (DST)
was performed by proportion method on LJ medium impreg-
natedwith isoniazid, rifampicin, streptomycin, and ethambu-
tol according to the proportion method as recommended by
WHO/IUATL [7].
GenoType MTBDRplus assay
The strip assay was performed as recommended by the man-
ufacturer [6]. Briefly, for amplification, 35 ll of a primer-nucle-
otide mixture (provided with the kit), 5 ll of buffer containing
2.5 mM MgCl2, 1.25 U Taq DNA polymerase, and 5 ll of the
preparation of mycobacterial DNA in a final volume of 50 ll
were used. The amplification protocol consisted of 15 min of
denaturing at 95 C; 10 cycles comprising 30 s at 95 C and
120 s at 58 C; an additional 20 cycles comprising 25 s at
95 C, 40 s at 53 C, and 40 s at 70 C; and a final extension at
70 C for 8 min. Hybridization and detection were performed
in a shaking incubator, and this procedure was performed
at 45 C for 30 min, followed by two washing steps. Steps ta-
ken to avoid amplicon contamination were manual pipetting
of the amplicon, use of separate wells and tubes for each
strip, and extensive rinsing after each use. After a final wash-
ing, strips were air dried and fixed on paper. For the sputum
specimens, an altered amplification protocol was applied
which consisted of 15 min of denaturing at 95 C; 10 cycles
comprising 30 s at 95 C and 120 s at 58 C; an additional 30
cycles comprising 25 s at 95 C, 40 s at 53 C, and 40 s at
70 C; and a final extension at 70 C for 8 min. Hybridization
and detection were performed as described above. Each strip
consists of 27 reaction zones (bands), including six controls
(conjugate, amplification, M. tuberculosis complex, rpoB, katG,
and inhA controls), eight rpoB wild-type (WT) and four mutant
probes (rpoB MUT D516V, rpoB MUT H526Y, rpoB MUT H526D,
and rpoB MUT S531L), one katG wild-type and two mutant
probes (katG MUT T1S315T1 and MUT T2S315T2), and two
inhA WTand four mutant probes (inhA MUT1C15T, inhAMU-
T2A16G, inhA MUT3A TBC, inhA TBA) (Fig. 1). Results were
interpreted according to the manufacturer’s instructions.
Laboratory quality control
Procedures for external quality assurance for smear and cul-
ture were based on the WHO guidelines [5]. The National Ref-
erence Laboratory before the start of the survey had
participated in external quality assurance proficiency tests.
The efficiency for determining INH and RIF resistance in
2009 was 100% using the conventional proportion method
as a standard by SRL of Research Institute of Tuberculosis, Ja-
pan (RIT) [7]. The efficiency for identifying INH- and RIF-resis-
tant strains using MTBDR plus assay was 99.0% and 91.6%,
respectively, considering the conventional proportion DST as
a standard.
Fig. 1 – Results for patterns of Genotype MTBDR plus strips (Hain Lifescience GmbH, Nehren, Germany). No. 1 – Negative control.
No. 2 – INH monoresistant (inhAC15T mutation). No. 3 – MDR TB (rpoB mutation in 530–533 region, katG S315T1 mutation).
No. 4 – MDR (rpoB S531L, katG S315T1 mutation). No. 5 – MDR (rpoB S531L, inhAC15T mutation). No. 6 –INHmono-resistant
(inhAC15T mutation). No. 7 – MDR (rpoB S531L, katG S315T1 mutation).
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The data were analyzed using SPSS 17.0 software. Sensitivity,
specificity, positive predictive and negative predictive values
of the molecular line probe assay were assessed compared
with conventional testing [8]. Reporting time was calculated
from the date of inoculation and the date of reporting of the
conventional DST result or the date of availability of the
molecular line probe assay.
Results
Study subjects
The study covered 218 MDR-TB subjects within the age range
of 14–75 years old from 8 districts of UB registered from 1 July
2009 to 30 May 2010. One hundred twenty-seven (127; 58.3%)
weremales and the remaining were female (91; 41.7%). A total
of 68 patients with exclusive criteria were excluded from the
study. A total of 150 patients with both results of MTBDR as-
say and conventional DST are subjects of this analysis.Table 1 – Genotype MTBDR and conventional drug susceptibility
from July 2009 to May 2010 in Ulaanbaatar, Mongolia.
Type Genot
No (%)
(n = 15
MDR 61 (40.
RIF monoresistant 5 (3.3)
INH monoresistant 10 (6.7
Susceptible to RIF and INH 75 (50.
Total 150 (10GenoType MTBDRplus testing from smear-positive sputum
The GenoType M. tuberculosis drug resistance first line
(MTBDRplus) assay (Hain Life-science, Nehren, Germany)
was used in the study. As shown in Table 1, of the total spec-
imens with conventional DST results, 75 (50.0%) were fully
susceptible strains, 61 (40.7%) were MDR, 5 (3.3%) were RIF
mono-resistant, 10 (6.7%) were INH mono-resistant. The re-
sults were comparatively analyzed with MTBDR plus assay.
A total of three discrepant results between LPA and DSTwere
observed. For detection of discrepancies, the samples were
compared with DNA sequencing results. The overall, sensitiv-
ity, specificity and positive and negative predictive values of
the specimens with rapid and conventional results are shown
in Table 2. Comparing the different banding patterns in drug-
resistant isolates, including MDR, RIF-mono-resistant and
INH-mono-resistant strains showed S531L mutation (MUT3
band) was more frequent and occurred in all RIF-resistant
strains (78.8%). Of all INH-resistant strains, 33.8% (37.7% of
MDR strains and 10% of INH-mono-resistant strains) had a
mutation (MUT1) in the katG, and 67.6% (63.9% of MDR strainstesting (DST) results of M. tuberculosis samples surveyed
ype MTBDR Conventional DST
No (%)
0) (n = 150)
7) 61 (40.7)
3 (2.7)
) 11 (7.3)
0) 75 (50.0)
0) 150 (100)
Table 2 – Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Genotype MTBDR plus in
detecting rifampicin and isoniazid resistance in smear and isolate samples.
Test characteristic Smear (n = 41) Isolate (n = 109) Total (n = 150)
RIF INH RIF INH RIF INH
Sensitivity 100 100 100 98.0 100 98.6
Specificity 100 100 98.5 100 98.8 100
PPV 100 100 96.9 100 98.9 100
NPV 100 100 100 98.8 100 98.3
Efficiency 100 100 99.1 99.1 99.3 99.3
kappa-coefficient 100 100 98.1 98.1 98.6 98.7
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(MUT1) in the inhA. Three strains had mutations in both the
katG and inhA. Nine of 10 (90%) INH-mono-resistant strains
were detected by the presence of a mutation in inhA only
(Table 3).
Discussion
The prevalence of identifiedMDR-TB cases was higher (40, 7%)
in Mongolian retreated cases. Using MTBDRplus assay, most
common mutations were rapidly and specifically detected
along with their resistance not only to RIF, but also to INH
in M. tuberculosis isolates (Tables 2 and 3). The probes used
in this assay combine targeting the 81-bp ‘‘hot-spot’’ region
in the rpoB gene, and two mutations at position 315 of the
katG gene. Mutations affecting this codon are responsible
for INH resistance in 60% of the cases worldwide [4]. In this
current research, of all INH-resistant strains, 33.8% (37.7% of
MDR strains and 10% of INH-mono-resistant strains) had a
mutation of MUT1 in the katG. High frequency of mutationsTable 3 – Pattern of Gene mutations in resistant Mycobacterium
Gene Band Gene region or Mutation MD
(n =
rpoB WT1 506–509 60
WT2 510–513 59
WT3 513–517 58
WT4 516–519 34
WT5 518–522 57
WT6 521–525 59
WT7 526–529 52
WT8 530–533 16
MUT1 D516V 4 (6
MUT2A H526Y 6 (9
MUT2B H526D 2 (3
MUT3 S531L 51
katG WT 315 38
MUT1 S315T1 23
MUT2 S315T2 3 (5
inhA WT1 215/216 21
WT2 28 59
MUT1 C15T 39
MUT2 A16G 1 (1
MUT3A T8C 1 (1
MUT3B T8A 0 (0were found in accordance with most available reports at
codons 531, 526, and 516. Although a high frequency of
S531L mutation (MUT3 band) was observed in all RIF-resistant
strains (83.6% of MDR), other mutations in the 530–533
regions also occurred; as detected by the lack of binding to
the WT8 probe in the absence of S531L mutation.
Based on previous review literature, frequencies of katG
mutation among INH resistantM. tuberculosis isolates in three
South American countries were as follows: Brazil (81.3%), Peru
(82.4%) and Argentina (71.4%). In contrast, the frequencies for
the katG S315T mutation in INH resistant M. tuberculosis iso-
lates for patients diagnosed in Kuwait and the Netherlands
(65% and 55%, respectively) was lower than what was de-
scribed in Russia (95%). Mutations in the inhA promoter region
was variable (15–35%) among INH-resistant M. tuberculosis
strains that were collected from the same geographical region
[9]. In this study, mutations in the promoter region of the inhA
gene played a major role (67.6% [63.9% of MDR strains and
90% of INH-mono-resistant strains]). Based on this finding,
inhA mutation may increase the capability of predicting INHtuberculosis strains using Genotype MTBDR plus assay.
R INH mono resistant RIF mono resistant
61) (n = 10) (n = 5)
(98.4) 10 (100) 5 (100)
(96.7) 10 (100) 5 (100)
(95.1) 10 (100) 5 (100)
(55.7) 10 (100) 2 (40)
(93.4) 10(100) 2 (40)
(96.7) 10 (100) 5 (100)
(85.2) 10 (100) 2 (40.0)
(21.3) 10 (100) 3 (60.0)
.6) 0 (0.0) 0 (0.0)
.8) 0 (0.0) 0 (0.0)
.3) 0 (0.0) 0 (0.0)
(83.6) 0 (0.0) 1 (20.0)
(63.3) 9 (90.0) 5 (100)
(37.7) 1 (10.0) 0 (0.0)
.0) 1 (10.0) 0 (0.0)
(34.4) 1 (10.0) 5 (100)
(96.7) 10 (100) 5 (100)
(63.9) 9 (90.0) 0 (0.0)
.6) 1 (10.0) 0 (0.0)
.6) 0 (0.0) 0 (0.0)
) 0 (0.0) 0 (0.0)
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GenoType MTBDRplus assay, which needs one day for ampli-
fication and another day for hybridization. Therefore, it will
take two to three days to interpret the results.Conclusions
Molecular-based rapid MDR screening with the GenoType
MTBDRplus test can be routinely used in a reference labora-
tory setting when rapid sensitivity testing is required for the
proper management of patients or for the contacts of drug
resistant cases. However, because only some of the mutations
are targeted, this molecular test cannot be considered to per-
form alone in the laboratory.
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